NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Price Target & More

$65.78 -1.92 (-2.84 %)
(As of 04/25/2018 06:36 AM ET)
Previous Close$67.70
Today's Range$65.30 - $68.44
52-Week Range$51.05 - $135.59
Volume601,400 shs
Average Volume916,376 shs
Market Capitalization$1.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta-1.82

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Debt-to-Equity Ratio21.71%
Current Ratio4.31%
Quick Ratio4.31%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$130.96 million
Price / Sales14.78
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book101.20

Profitability

EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-275.18%
Return on Equity-267.95%
Return on Assets-61.90%

Miscellaneous

Employees507
Outstanding Shares29,430,000

How to Become a New Pot Stock Millionaire

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals (NASDAQ:ICPT) posted its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.39) by $1.04. The biopharmaceutical company earned $37.69 million during the quarter, compared to analysts' expectations of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. Intercept Pharmaceuticals's revenue for the quarter was up 173.1% on a year-over-year basis. During the same quarter last year, the company earned ($4.84) earnings per share. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Intercept Pharmaceuticals.

What price target have analysts set for ICPT?

21 brokers have issued twelve-month price targets for Intercept Pharmaceuticals' stock. Their predictions range from $50.00 to $256.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $128.5263 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept’s fourth-quarter results missed expectations as sales of Ocaliva declined due to safety issues surrounding the drug. The approval of Ocaliva was a significant boost for Intercept. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. The company also announced an updated label for Ocaliva in the United States, reinforcing appropriate dosing in PBC patients with Child-P Class B or C or decompensated cirrhosis. While the updated label should help the stock turn around, it might be a while before the sales start to recover. First-quarter is expected to be a transitional quarter. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC. Given the challenges faced by the drug in recent times, the label expansion of OCA will boost the growth prospects. Shares have underperformed the industry in the last six months." (2/19/2018)
  • 2. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
  • 3. Cantor Fitzgerald analysts commented, "Emerging Safety Risks, but PBC Remains Intact. This morning, Intercept reported results demonstrating 3Q17 revenue growth to $36.8 million (excl. $4.1 million one-time increase in deferred revenue) from $31 million in 2Q17. While the FDA warning letter at the end of the quarter potentially shifts the risk-benefit profile of Ocaliva, an analysis of drug scripts provided by Intercept indicates that the sharp drop in scripts around the time of the news has since abated. Net ex-U.S 3Q17 sales increased to $4.7 million from $2.5 million in 2Q17 during the quarter, largely contributed from Germany and France. No formal guidance for the full-year was given, but management noted that they expect sequential quarterly growth for the balance of 2017. While we do not see a negative impact to our long-run commercialization in PBC, we believe the safety events reaffirm the uncertainty for Ocaliva’s use in NASH (where dosing is higher)." (11/1/2017)
  • 4. Wells Fargo analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
  • 5. Cowen Inc analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
  • Dr. David Shapiro M.D., Ph.D., Chief Medical Officer (Age 64)
  • Ms. Lisa Bright B.Sc., Pres of International (Age 50)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 50)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

Headlines about ICPT stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include GENEXTRA S.P.A. (23.30%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $65.78.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $1.99 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  775 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  1,173
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Intercept Pharmaceuticals in the last 12 months. Their average twelve-month price target is $128.5263, suggesting that the stock has a possible upside of 95.39%. The high price target for ICPT is $256.00 and the low price target for ICPT is $50.00. There are currently 3 sell ratings, 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.362.24
Ratings Breakdown: 3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $128.5263$128.3684$134.80$153.85
Price Target Upside: 95.39% upside106.11% upside117.67% upside148.47% upside

Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History

Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018WedbushLower Price TargetOutperform -> Outperform$203.00 -> $256.00LowView Rating Details
3/28/2018Needham & Company LLCReiterated RatingHoldMediumView Rating Details
3/20/2018OppenheimerReiterated RatingHoldLowView Rating Details
2/15/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$152.00 -> $155.00HighView Rating Details
2/14/2018Cantor FitzgeraldSet Price TargetHold$58.00HighView Rating Details
2/13/2018Wells FargoReiterated RatingMarket Perform$62.00 -> $57.00MediumView Rating Details
2/12/2018Deutsche BankInitiated CoverageBuy$103.00MediumView Rating Details
2/7/2018Goldman SachsDowngradeNeutral -> SellLowView Rating Details
1/25/2018Robert W. BairdReiterated RatingOutperform$332.00 -> $253.00LowView Rating Details
1/22/2018Credit Suisse GroupSet Price TargetBuy$201.00 -> $167.00HighView Rating Details
12/29/2017CitigroupSet Price TargetHold$74.00HighView Rating Details
11/28/2017Leerink SwannReiterated RatingHold$60.00LowView Rating Details
11/1/2017CowenReiterated RatingBuy$112.00N/AView Rating Details
11/1/2017LaidlawUpgradeHold -> Buy$90.00N/AView Rating Details
10/13/2017Bank of AmericaLower Price TargetUnderperform$102.00 -> $73.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/AView Rating Details
10/4/2017Royal Bank of CanadaReiterated RatingOutperform -> OutperformHighView Rating Details
10/4/2017JMP SecuritiesDowngradeOutperform -> Market PerformHighView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$275.00 -> $135.00LowView Rating Details
9/22/2017UBSDowngradeOutperform -> Market PerformLowView Rating Details
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 -> $50.00HighView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
6/1/2016BarclaysReiterated RatingBuy$200.00 -> $205.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings History and Estimates Chart

Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings Estimates

2018 EPS Consensus Estimate: ($13.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($3.71)($3.32)($3.44)
Q2 20184($4.12)($2.89)($3.36)
Q3 20184($4.63)($2.81)($3.36)
Q4 20184($5.23)($2.74)($3.57)

Intercept Pharmaceuticals (NASDAQ ICPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($3.38)N/AView Earnings Details
2/14/2018Q4 2017($3.39)($4.43)$39.01 million$37.69 millionViewN/AView Earnings Details
11/1/2017Q3 2017($3.48)($2.89)$36.95 million$41.33 millionViewN/AView Earnings Details
7/31/2017Q2 2017($3.62)($3.46)$27.50 million$30.89 millionViewN/AView Earnings Details
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)$0.41 million$0.41 millionViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 million$0.41 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.4050 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.44)($0.62)$1.23 million$0.41 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.37)($0.43)ViewN/AView Earnings Details
11/26/2012Q3 2012($0.57)($1.86)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Intercept Pharmaceuticals (NASDAQ:ICPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 63.29%
Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/9/2018Francesco MicheliMajor ShareholderBuy390,625$64.00$25,000,000.00View SEC Filing  
4/9/2018Keith Michael GottesdienerDirectorBuy1,171$64.00$74,944.005,001View SEC Filing  
4/9/2018Mark PruzanskiCEOBuy7,812$64.00$499,968.0011,642View SEC Filing  
10/2/2017David ShapiroCMOSell349$58.90$20,556.10View SEC Filing  
10/2/2017Mark PruzanskiCEOSell1,532$58.87$90,188.84View SEC Filing  
10/2/2017Rachel McminnInsiderSell283$58.89$16,665.87View SEC Filing  
10/2/2017Richard J KimSVPSell48$58.10$2,788.80View SEC Filing  
10/2/2017Sandip KapadiaCFOSell354$58.83$20,825.82View SEC Filing  
9/1/2017David ShapiroCMOSell1,250$117.43$146,787.5045,812View SEC Filing  
8/25/2017Lisa BrightInsiderSell253$111.31$28,161.4323,324View SEC Filing  
8/2/2017Lisa BrightInsiderSell142$110.29$15,661.1823,477View SEC Filing  
8/1/2017David ShapiroCMOSell1,118$119.00$133,042.0045,680View SEC Filing  
7/31/2017Daniel G WelchDirectorSell602$123.93$74,605.863,108View SEC Filing  
7/31/2017Rachel McminnInsiderSell130$123.12$16,005.6017,158View SEC Filing  
7/20/2017Daniel G WelchDirectorSell217$126.76$27,506.923,710View SEC Filing  
7/14/2017Richard J KimSVPSell89$128.64$11,448.9611,253View SEC Filing  
7/11/2017David ShapiroCMOSell553$124.01$68,577.5344,562View SEC Filing  
7/3/2017David ShapiroCMOSell350$121.24$42,434.0045,215View SEC Filing  
7/3/2017Lisa BrightInsiderSell394$121.33$47,804.0223,619View SEC Filing  
7/3/2017Mark PruzanskiCEOSell1,434$121.78$174,632.52570,284View SEC Filing  
7/3/2017Richard J KimSVPSell50$121.69$6,084.5011,342View SEC Filing  
7/3/2017Sandip KapadiaCFOSell1,431$121.59$173,995.2920,569View SEC Filing  
6/26/2017Mark PruzanskiCEOSell40,000$130.80$5,232,000.00611,718View SEC Filing  
6/1/2017Lisa BrightInsiderSell698$110.73$77,289.5424,711View SEC Filing  
5/25/2017Lisa BrightInsiderSell254$117.52$29,850.0823,246View SEC Filing  
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.6223,613View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.0023,804View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.0646,582View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.6817,545View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.5845,465View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.0046,023View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.0022,925View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00571,718View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.9221,695View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.6417,383View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.6540,369View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.9641,934View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84552,705View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.7212,916View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.5042,922View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.4018,209View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.7813,732View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.7444,272View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.4030,661View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.0446,196View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.0018,305View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00552,020View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.6045,732View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00579,314View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.0018,460View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.2513,861View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.5018,855View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.7014,087View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.4430,948View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.4048,546View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.2819,106View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08548,248View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.0219,259View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.687,621View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.5611,700View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.2024,892View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.7040,911View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40529,556View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.107,749View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.0012,428View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.9228,395View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.0029,159View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.002,166View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.008,218View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.1824,062View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.8029,159View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86962View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.0023,527View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00470,174View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00470,174View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.0013,510View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.781,640View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.007,041View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.1913,679View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.4413,124View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.961,655View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00430,298View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.001,943View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.808,663View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.991,640View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.946,392View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.763,000View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.005,094View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00402,032View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00402,032View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.005,094View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.204,266View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.162,532View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00402,032View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.671,330View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines

Source:
DateHeadline
Intercept Pharmaceuticals (ICPT) to Release Earnings on WednesdayIntercept Pharmaceuticals (ICPT) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 3:52 AM
Intercept Pharma (ICPT) Announces Nancy Miller-Rich to BoardIntercept Pharma (ICPT) Announces Nancy Miller-Rich to Board
www.streetinsider.com - April 24 at 5:16 PM
Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of DirectorsIntercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors
finance.yahoo.com - April 24 at 8:42 AM
Research Analysts Set Expectations for Intercept Pharmaceuticals Incs Q1 2018 Earnings (ICPT)Research Analysts Set Expectations for Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT)
www.americanbankingnews.com - April 19 at 7:08 AM
BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to "Buy"BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to "Buy"
www.americanbankingnews.com - April 18 at 10:06 AM
Jefferies Group Weighs in on Intercept Pharmaceuticals Incs Q1 2018 Earnings (ICPT)Jefferies Group Weighs in on Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT)
www.americanbankingnews.com - April 18 at 7:54 AM
Intercept Pharmaceuticals (ICPT) Given New $256.00 Price Target at WedbushIntercept Pharmaceuticals (ICPT) Given New $256.00 Price Target at Wedbush
www.americanbankingnews.com - April 17 at 8:49 AM
Intercept Reports Phase III Sub-Study Liver Biopsy DataIntercept Reports Phase III Sub-Study Liver Biopsy Data
www.zacks.com - April 16 at 5:01 PM
Intercept Pharmaceuticals (ICPT) Receives Hold Rating from LaidlawIntercept Pharmaceuticals (ICPT) Receives Hold Rating from Laidlaw
www.americanbankingnews.com - April 14 at 2:30 PM
11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA)11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA)
globenewswire.com - April 13 at 8:55 AM
Intercept Pharmas obeticholic acid shows positive effect on fibrosis and cirrhosis in late-stage study; shares up 3% premarketIntercept Pharma's obeticholic acid shows positive effect on fibrosis and cirrhosis in late-stage study; shares up 3% premarket
seekingalpha.com - April 13 at 8:55 AM
CymaBay Therapeutics Pushes Itself To The Next Stage Against Rare Liver DiseaseCymaBay Therapeutics Pushes Itself To The Next Stage Against Rare Liver Disease
seekingalpha.com - April 12 at 9:21 AM
 Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Quarterly Sales of $38.55 Million Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Quarterly Sales of $38.55 Million
www.americanbankingnews.com - April 10 at 2:56 AM
Intercept Pharmaceuticals Inc (ICPT) CEO Acquires $499,968.00 in StockIntercept Pharmaceuticals Inc (ICPT) CEO Acquires $499,968.00 in Stock
www.americanbankingnews.com - April 9 at 10:26 PM
Intercept Pharmaceuticals Inc (ICPT) Director Keith Michael Gottesdiener Acquires 1,171 SharesIntercept Pharmaceuticals Inc (ICPT) Director Keith Michael Gottesdiener Acquires 1,171 Shares
www.americanbankingnews.com - April 9 at 10:26 PM
Intercept Pharmaceuticals Inc (ICPT) Major Shareholder Francesco Micheli Purchases 390,625 SharesIntercept Pharmaceuticals Inc (ICPT) Major Shareholder Francesco Micheli Purchases 390,625 Shares
www.americanbankingnews.com - April 9 at 7:16 PM
A Look at Intercept Pharmaceuticals’ Cash FlowsA Look at Intercept Pharmaceuticals’ Cash Flows
finance.yahoo.com - April 9 at 8:54 AM
Royal Bank of Canada Raises Intercept Pharmaceuticals (ICPT) Price Target to $244.00Royal Bank of Canada Raises Intercept Pharmaceuticals (ICPT) Price Target to $244.00
www.americanbankingnews.com - April 8 at 5:25 PM
 Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Earnings of -$3.42 Per Share Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Earnings of -$3.42 Per Share
www.americanbankingnews.com - April 8 at 3:10 PM
Intercept Pharmaceuticals (ICPT) Cut to "Market Perform" at JMP SecuritiesIntercept Pharmaceuticals (ICPT) Cut to "Market Perform" at JMP Securities
www.americanbankingnews.com - April 7 at 10:28 PM
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in AprilAnalysts’ Ratings for Enanta Pharmaceuticals and Peers in April
finance.yahoo.com - April 7 at 9:04 AM
Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% HigherIntercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher
www.zacks.com - April 6 at 8:56 AM
Today’s Research Reports on Stocks to Watch: Intercept Pharmaceuticals and Conatus PharmaceuticalsToday’s Research Reports on Stocks to Watch: Intercept Pharmaceuticals and Conatus Pharmaceuticals
finance.yahoo.com - April 6 at 8:56 AM
Analysts’ Ratings for Intercept Pharmaceuticals in AprilAnalysts’ Ratings for Intercept Pharmaceuticals in April
finance.yahoo.com - April 6 at 8:56 AM
Intercept Pharma (ICPT) Plans $120 Million Public Offering of Common Stock, Concurrent $92 Million Private PlacementIntercept Pharma (ICPT) Plans $120 Million Public Offering of Common Stock, Concurrent $92 Million Private Placement
www.streetinsider.com - April 5 at 4:59 PM
Why Tesla, Marathon Oil, and Intercept Pharmaceuticals Jumped TodayWhy Tesla, Marathon Oil, and Intercept Pharmaceuticals Jumped Today
finance.yahoo.com - April 5 at 4:59 PM
Intercept Pharmaceuticals (ICPT) Stock Rating Upgraded by ValuEngineIntercept Pharmaceuticals (ICPT) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM
Intercept Pharma prices upsized stock offering at $64; shares up 1% premarketIntercept Pharma prices upsized stock offering at $64; shares up 1% premarket
seekingalpha.com - April 5 at 10:47 AM
Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common StockIntercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock
finance.yahoo.com - April 5 at 10:47 AM
Intercept Pharmaceuticals (ICPT) Upgraded at LaidlawIntercept Pharmaceuticals (ICPT) Upgraded at Laidlaw
www.americanbankingnews.com - April 2 at 11:16 AM
Intercept Pharmaceuticals Inc (ICPT) Given Consensus Rating of "Hold" by AnalystsIntercept Pharmaceuticals Inc (ICPT) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 31 at 8:11 AM
Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by Zacks Investment ResearchIntercept Pharmaceuticals (ICPT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:49 PM
Needham & Company LLC Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)Needham & Company LLC Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - March 28 at 9:16 PM
BidaskClub Lowers Intercept Pharmaceuticals (ICPT) to Strong SellBidaskClub Lowers Intercept Pharmaceuticals (ICPT) to Strong Sell
www.americanbankingnews.com - March 28 at 12:34 AM
Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by ValuEngineIntercept Pharmaceuticals (ICPT) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 25 at 5:24 PM
Intercept Pharmaceuticals (ICPT) Downgraded by Goldman SachsIntercept Pharmaceuticals (ICPT) Downgraded by Goldman Sachs
www.americanbankingnews.com - March 25 at 7:44 AM
$38.55 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter$38.55 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter
www.americanbankingnews.com - March 24 at 4:49 AM
Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018
finance.yahoo.com - March 23 at 8:47 AM
Intercept Pharmaceuticals (ICPT) "Hold" Rating Reaffirmed at OppenheimerIntercept Pharmaceuticals' (ICPT) "Hold" Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - March 21 at 7:48 PM
New Research: Key Drivers of Growth for LTC Properties, NACCO Industries, Viad, Resource Capital, WageWorks, and Intercept Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for LTC Properties, NACCO Industries, Viad, Resource Capital, WageWorks, and Intercept Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - March 21 at 9:36 AM
Edited Transcript of ICPT earnings conference call or presentation 14-Feb-18 1:30pm GMTEdited Transcript of ICPT earnings conference call or presentation 14-Feb-18 1:30pm GMT
finance.yahoo.com - March 21 at 9:36 AM
Intercept (ICPT) Up 6.7% Since Earnings Report: Can It Continue?Intercept (ICPT) Up 6.7% Since Earnings Report: Can It Continue?
finance.yahoo.com - March 16 at 6:05 PM
CORRECTING and REPLACING -- Intercept to Present at Upcoming ConferenceCORRECTING and REPLACING -- Intercept to Present at Upcoming Conference
finance.yahoo.com - March 13 at 6:57 PM
Intercept Pharmaceuticals Inc to Post FY2021 Earnings of $10.38 Per Share, Wedbush Forecasts (ICPT)Intercept Pharmaceuticals Inc to Post FY2021 Earnings of $10.38 Per Share, Wedbush Forecasts (ICPT)
www.americanbankingnews.com - March 12 at 9:41 AM
Intercept Pharmaceuticals (ICPT) Earns Outperform Rating from WedbushIntercept Pharmaceuticals (ICPT) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - March 9 at 8:11 AM
Research finds female analysts are more accurate, make bolder calls - CNBCResearch finds female analysts are more accurate, make bolder calls - CNBC
www.cnbc.com - March 8 at 6:10 PM
$38.46 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter$38.46 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter
www.americanbankingnews.com - March 7 at 1:59 PM
Intercept Pharmaceuticals Inc (ICPT) Receives Average Rating of "Hold" from AnalystsIntercept Pharmaceuticals Inc (ICPT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 6 at 1:39 PM
Hudson Bay Capital Management LP Invests $1.75 Million in Intercept Pharmaceuticals Inc (ICPT) StockHudson Bay Capital Management LP Invests $1.75 Million in Intercept Pharmaceuticals Inc (ICPT) Stock
www.americanbankingnews.com - March 2 at 12:49 PM
Altrinsic Global Advisors LLC Grows Stake in Intercept Pharmaceuticals Inc (ICPT)Altrinsic Global Advisors LLC Grows Stake in Intercept Pharmaceuticals Inc (ICPT)
www.americanbankingnews.com - March 2 at 4:16 AM

SEC Filings

Intercept Pharmaceuticals (NASDAQ:ICPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intercept Pharmaceuticals (NASDAQ:ICPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intercept Pharmaceuticals (NASDAQ ICPT) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.